> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By Nigel Somerville | Saturday 7 September 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Neil Woodford’s benchmark for his Equity Income Fund (WEIF) and Income Focus Fund (WIFF) put on 0.19% yesterday. For the second day in a row WIFF and WEIF both beat that, putting on 0.69% and 0.40% in NAV per unit respectively. Meanwhile, Neil has been selling more Norwegian Dog Thin Film (THIN), dropping his holding to 9.86% as announced at no-one-is-watching o’clock last night (at quarter to five) as the company continues to hurtle towards the corporate undertakers or an eye-watering dilution if a rescue refinancing can be arranged.
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen